Join Growin Stock Community!

Alto neuroscience, inc.ANRO.US Overview

US StockHealthcare
(No presentation for ANRO)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ANRO AI Insights

ANRO Overall Performance

ANRO AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ANRO Recent Performance

2.74%

Alto neuroscience, inc.

0.05%

Avg of Sector

-0.31%

S&P500

ANRO PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ANRO Key Information

ANRO Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ANRO Profile

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and post-traumatic stress disorder; ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties to treat patients with MDD; and ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor for the treatment of cognitive impairment associated with schizophrenia. It also develops ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist to treat patients with MDD and higher levels of anhedonia, and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor for the treatment of MDD. In addition, the company develops novel pharmacodynamically synergistic combinations and an AI-enabled biomarker platform that combine sources of information on patients brain activity and behavior to identify patients to respond to novel product candidates. Alto Neuroscience, Inc. was incorporated in 2019 and is based in Los Altos, California.

Price of ANRO

ANRO FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ANRO Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.00
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
5.37
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.00
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
5.37
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is ANRO's latest earnings report released?

    The most recent financial report for Alto neuroscience, inc. (ANRO) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ANRO's short-term business performance and financial health. For the latest updates on ANRO's earnings releases, visit this page regularly.

  • How much cash does ANRO have?

    At the end of the period, Alto neuroscience, inc. (ANRO) held Total Cash and Cash Equivalents of 138.32M, accounting for 0.94 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is ANRO's EPS continuing to grow?

    According to the past four quarterly reports, Alto neuroscience, inc. (ANRO)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.52. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ANRO?

    Alto neuroscience, inc. (ANRO)'s Free Cash Flow (FCF) for the period is -9.92M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 22.1% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.